Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 56, Issue 1, 2007, Pages 129-134

  Diamanti Kandarakis, Evanthia ^a   Alexandraki, Krystallenia ^a   Piperi, Christina ^a   Aessopos, Athanasios ^a   Paterakis, Thomas ^a   Katsikis, Ilias ^b   Panidis, Dimitrios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Medical School   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANDROGEN; METFORMIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HUMAN; MEASUREMENT; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 33845217088     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.09.006     Document Type: Article

References (32)

1. Diamanti-Kandarakis E., and Dunaif A. New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab 7 (1996) 267-271
2. Diamanti-Kandarakis E., Spina G., Kouli C., and Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86 (2001) 4666-4673
3. Diamanti-Kandarakis E., Palioniko G., Alexandraki K., Bergiele A., Koutsouba T., and Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 150 (2004) 795-800
4. Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
5. Sabuncu T., Vural H., Harma M., and Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34 (2001) 407-413
6. Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Katsilambros N., Aessopos A., et al. Indices of low grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21 (2006) 1426-1431
7. Diamanti-Kandarakis E., Piperi C., Alexandraki K., Katsilambros N., Kouroupi E., Papailiou J., et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metab Clin Exp 55 (2006) 494-500
8. Vlassara H., and Palace M.R. Diabetes and advanced glycation endproducts. J Intern Med 251 (2002) 87-101
9. Vlassara H., Bucala R., and Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70 (1994) 138-151
10. Makino H., Shikata K., Hironaka K., Kushiro M., Yamasaki Y., Sugimoto H., et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 48 (1995) 517-526
11. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91 (1993) 2470-2478
12. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus, I. The AGE concept. Cardiovasc Res 37 (1998) 586-600
13. Miyata T., Maeda K., Kurokawa K., and van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12 (1997) 255-258
14. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., and Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301 (2000) 65-77
15. Beisswenger P., and Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 29 (2003) 6S95-6S103
16. Velazguez E.M., Mendosa S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in PCO reduces hyperinsulinemia, insulin resistance, hyperandrogenism. Metabolism 43 (1994) 647-654
17. Nestler J.E., and Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335 (1996) 617-623
18. Diamanti-Kandarakis E., Kouli C.R., Tsianateli T.C., and Bergiele A.T. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138 (1998) 269-274
19. Beisswenger P.J., Howell S.K., Touchette A.D., Lal S., and Szwergold B.S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48 (1999) 198-202
20. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
21. Sakata N., Imanaga Y., Meng J., et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 141 (1998) 61-75
22. Diamanti-Kandarakis E., Piperi C., Kalofoutis A., and Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62 (2005) 37-43
23. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
24. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
25. Ruggiero-Lopez D., Lecomte M., Moinet G., Patereau G., Lagarde M., and Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58 (1999) 1765-1773
26. Kiho T., Kato M., Usui S., and Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clin Chim Acta 358 (2005) 139-145
27. Tanaka Y., Uchino H., Shimizu T., Yoshii H., Niwa M., Ohmura C., et al. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 376 (1999) 17-22
28. Sano H., Higashi T., Matsumoto K., Melkko J., Jinnouchi Y., Ikeda K., et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem 273 (1998) 8630-8637
29. Dunaif A., Wu X.Q., Lee A., and Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol 281 (2001) E392-E399
30. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352 (1998) 854-865
31. Abassi F., and Reaven G.M. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 51 (2002) 235-237
32. Diamanti-Kandarakis E., Kouli C., Alexandraki K., and Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 1273-1276